NPS Finds Hidden Value In Orphan Diseases
This article was originally published in The Pink Sheet Daily
A recently presented Mayo Clinic study shows that there might be more value in a rare orphan disease than NPS previously estimated.
You may also be interested in...
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.
The biotech is shifting gears after clinical hold on its lead drug was unlikely to be lifted, but the early-stage candidate that it's placing its hopes on is raising red flags for analysts and investors.
The biotech confirmed that a recent death during a clinical trial was not caused by its early-stage gene therapy.